Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Office of Pharmaceutical Manufacturing Assessment, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
Front Immunol. 2024 May 28;15:1376096. doi: 10.3389/fimmu.2024.1376096. eCollection 2024.
Bispecific T-cell-engaging antibodies are a growing class of therapeutics with numerous molecules being tested in clinical trials and, currently, seven of them have received market approval. They are structurally complex and function as adaptors to redirect the cytotoxicity of T cells to kill tumor cells. T-cell-engaging bispecific antibodies can be generally divided into two categories: IgG/IgG-like and non-IgG-like formats. Different formats may have different intrinsic potencies and physiochemical properties, and comprehensive studies are needed to gain a better understanding of how the differences in formats impact on structural and functional characteristics. In this study, we designed and generated bispecific T-cell-engaging antibodies with IgG-like (DVD-Ig) and non-IgG (BiTE) formats. Both target the same pair of antigens (EGFR and CD3) to minimize the possible influence of targets on functional characterization. We performed a side-by-side comparison to assess differences in the physiochemical and biological properties of these two bispecific T-cell-engaging antibodies using a variety of breast and ovarian cancer cell-based functional assays to delineate the structural-functional relationships and anti-tumor activities/potency. We found that the Fc portion of T-cell-engaging bispecific antibodies can significantly impact antigen binding activity, potency, and stability in addition to eliciting different mechanisms of action that contribute the killing of cancer cells.
双特异性 T 细胞接合抗体是一类不断发展的治疗药物,有许多分子正在临床试验中进行测试,目前已有七种获得了市场批准。它们结构复杂,作为衔接子将 T 细胞的细胞毒性重定向以杀死肿瘤细胞。T 细胞接合双特异性抗体通常可分为两类:IgG/IgG 样和非 IgG 样格式。不同的格式可能具有不同的内在效力和物理化学特性,需要进行综合研究以更好地了解格式的差异如何影响结构和功能特性。在这项研究中,我们设计并生成了具有 IgG 样(DVD-Ig)和非 IgG 样(BiTE)格式的双特异性 T 细胞接合抗体。这两种抗体都针对相同的抗原对(EGFR 和 CD3),以最大程度地减少目标对功能特征的可能影响。我们进行了并排比较,使用各种乳腺癌和卵巢癌细胞功能测定来评估这两种双特异性 T 细胞接合抗体在物理化学和生物学特性方面的差异,以阐明结构-功能关系和抗肿瘤活性/效力。我们发现,T 细胞接合双特异性抗体的 Fc 部分除了引发不同的作用机制导致癌细胞杀伤外,还可以显著影响抗原结合活性、效力和稳定性。